Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Alcon Research
ClinicalTrials.gov Identifier:
NCT00966940
First received: August 26, 2009
Last updated: May 18, 2012
Last verified: May 2012
  Purpose

The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.


Condition Intervention Phase
Glaucoma
Drug: Travoprost 0.004% ophthalmic solution (TRAVATAN)
Drug: Tafluprost 0.0015% ophthalmic solution
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: The Efficacy and Safety of Travoprost, 0.004% Versus Tafluprost, 0.0015% in Primary Open-Angle Glaucoma or Ocular Hypertensive Patients

Resource links provided by NLM:


Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Mean Intraocular Pressure (IOP) at 8:00 PM [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Intraocular pressure was measured by Goldmann applanation tonometry.


Secondary Outcome Measures:
  • Mean Intraocular Pressure (IOP) at 8:00 AM [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Intraocular pressure was measured by Goldmann applanation tonometry.

  • Mean Intraocular Pressure (IOP) at 10:00 AM [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Intraocular pressure was measured by Goldmann applanation tonometry.

  • Mean Intraocular Pressure (IOP) at 12:00 PM [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Intraocular pressure was measured by Goldmann applanation tonometry.

  • Mean Intraocular Pressure (IOP) at 2:00 PM [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Intraocular pressure was measured by Goldmann applanation tonometry.

  • Mean Intraocular Pressure (IOP) at 4:00 PM [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Intraocular pressure was measured by Goldmann applanation tonometry.

  • Mean Intraocular Pressure (IOP) at 6:00 PM [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Intraocular pressure was measured by Goldmann applanation tonometry.


Enrollment: 51
Study Start Date: September 2009
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Travoprost-to-tafluprost
Travoprost first, with tafluprost second. Each product dosed for six weeks.
Drug: Travoprost 0.004% ophthalmic solution (TRAVATAN)
One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
Other Name: TRAVATAN
Drug: Tafluprost 0.0015% ophthalmic solution
One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
Tafluprost-to-travoprost
Tafluprost first, with travoprost second. Each product dosed for six weeks.
Drug: Travoprost 0.004% ophthalmic solution (TRAVATAN)
One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
Other Name: TRAVATAN
Drug: Tafluprost 0.0015% ophthalmic solution
One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • An EC-reviewed and approved (for use in this study) informed consent form must be read, signed, and dated by the participating patient as well as signed and dated by the individual (Principal Investigator or other site personnel) obtaining the informed consent, before conducting the Screening Visit and prior to initiation of study procedures.
  • Patients must be at least 21 years of age.
  • Must be able to follow instructions and be willing and able to attend required study visits.
  • Must have a clinical diagnosis of ocular hypertension or primary open-angle glaucoma in at least one eye (qualifying eye).
  • Currently treated patients, in the investigator's judgment, should require a change in treatment for reasons of improved efficacy, tolerability or compliance.
  • Must have IOP considered to be safe, in both eyes, in such a way that should assure clinical stability of vision and the optic nerve throughout the trial.
  • Must have an intraocular pressure of > 21 mm Hg in at least one eye at 08:00 and > 19 mm Hg in the same eye at 16:00, and < 35 mm Hg in both eyes at all diurnal time points at Visit 2.
  • Must have best corrected visual acuity of 6/60 (20/200 Snellen) or better in each eye.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

  • Presence of other primary or secondary glaucomas not listed in inclusion criterion.
  • Presence of extreme narrow angle with complete or partial closure in either eye, as measured by gonioscopy (occludable angles treated with a patent iridectomy are acceptable).
  • Any abnormality preventing reliable applanation tonometry in qualifying eye(s).
  • Any opacity or patient uncooperativeness that restricts adequate examination of the ocular fundus or anterior chamber of either eye.
  • Concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye. Blepharitis or non-clinically significant conjunctival injection is allowed.
  • Intraocular conventional surgery or laser surgery in qualifying eye(s) less than three months prior to Visit 1.
  • Risk of visual field or visual acuity worsening as a consequence of participation in the trial, in the investigator's best judgment.
  • Progressive retinal or optic nerve disease from any cause apart from glaucoma.
  • Women of childbearing potential not using reliable means of birth control, or pregnant or lactating females.
  • Any clinically significant, serious, or severe medical or psychiatric condition.
  • A condition, which in the opinion of the investigator, would interfere with optimal participation in the study, or which would present a special risk to the patient.
  • Participation in any other investigational study within 30 days prior to Visit 2.
  • Known medical history of allergy or sensitivity to any components of the preparations to be used in this trial that is deemed clinically significant in the opinion of the investigator.
  • Use of systemic medications known to affect IOP (e.g., oral beta-adrenergic blockers,alpha-agonists and blockers, angiotensin converting enzyme inhibitors and calcium channel blockers), which have not been on a stable course for 7 days prior to Visit 2 or an anticipated change in the dosage during the course of the study.
  • Anticipated use of systemic corticosteroids, by any route except inhaled, for greater than two weeks during the trial.
  • A history of, or at risk for uveitis or cystoid macular edema (CME).
  • History of ocular herpes simplex.
  • Unwillingness to accept the risk of iris, skin, or eyelash changes associated with prostaglandin therapy.
  • Other protocol-defined exclusion criteria may apply.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT00966940     History of Changes
Other Study ID Numbers: SMA-08-16
Study First Received: August 26, 2009
Results First Received: February 9, 2011
Last Updated: May 18, 2012
Health Authority: Germany: Ethics Commission

Keywords provided by Alcon Research:
Glaucoma
IOP
Travoprost

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Glaucoma
Ocular Hypertension
Eye Diseases
Pharmaceutical Solutions
Ophthalmic Solutions
Travoprost
Cloprostenol
Therapeutic Uses
Pharmacologic Actions
Antihypertensive Agents
Cardiovascular Agents
Luteolytic Agents
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 22, 2014